For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 81,983 | |||
| General and administrative | 21,245 | |||
| Total operating expenses | 103,228 | |||
| Loss from operations | -103,228 | |||
| Interest income | 1,040 | |||
| Change in fair value of the tranche rights | 0 | |||
| Other income (expense), net | 5,016 | |||
| Total other income (expense), net | 6,056 | |||
| Net loss | -97,172 | |||
| Basic EPS | -0.62 | |||
| Diluted EPS | -0.62 | |||
| Basic Average Shares | 155,688,030 | |||
| Diluted Average Shares | 155,688,030 | |||
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)